IGY 112
Alternative Names: IGY-112Latest Information Update: 28 Jul 2024
At a glance
- Originator IGY Life Sciences
- Class Antibodies; Irritable bowel syndrome therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Inflammatory-bowel-diseases in Canada (Parenteral)
- 17 Jun 2020 IGY 112 is available for licensing as of 17 Jun 2020. https://www.igylifesciences.com/
- 17 Jun 2020 Early research in Inflammatory bowel diseases in Canada (Parenteral) (IGY Life Sciences pipeline, June 2020)